Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
A large population based cohort utilizing the TriNetX research database found a mean reduction in BMI of 1.635 kg/m 2 at 1 year in 4,968 IIH patients prescribed GLP-1RAs compared to 0.758 kg/m 2 in controls (17)
With their favorable safety profiles and demonstrated efficacy, GLP-1 agonists continue to garner attention as promising therapeutic agents beyond the realm of diabetes
They have both gone through extensive clinical programmes, including cardiovascular outcomes trials, and have shown beneficial effects [22, 26, 27]
In February 2020, Trulicity was approved by the US FDA for new indications for use in adult patients with type 2 diabetes who have cardiovascular (CV) diseases or multiple cardiovascular risk factors to reduce the risk of major adverse cardiovascular events (MACE)
US$ 25.94
US$ 20.05
US$ 23.45
US$ 21.19
US$ 27.95
US$ 29.22
